CMS Open Payments · Program Year 2024
Xiros Limited
Xiros Limited reported $2,625.00 across General Payments, Research, and Ownership to 1 physicians and teaching hospitals across 1 transactions.
- $2.6K
- All-tracks total
- 1
- Transactions
- 1
- Recipients
- #1772
- of 1,925 companies
Xiros Limited reported $2,625.00 across all CMS Open Payments tracks (General + Research + Ownership) to 1 physicians and teaching hospitals in Program Year 2024 - ranking #1772 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,625.00, averaging $2.6K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer xiros-limited Xiros Limited
$2.6K · #1772/1,925 · 0.0% industry · PY2024
- TOT $2.6K
- RANK #1772
- SHARE 0.0%
- TXN 1
- RCP 1
- CAT 1
- GEN $2.6K
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: EDW Pharma, Inc. ($2.6K)
Xiros Limited sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Xiros Limited
In Program Year 2024, Xiros Limited reported $2,625.00 in payments to 1 physicians and teaching hospitals across 1 individual transactions, an average of $2.6K per transaction and $2.6K per recipient. That total places Xiros Limited at rank #1772 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 1 general-payment categories charted below, "Consulting Fee" is the largest at $2.6K across 1 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Xiros Limited's 1-category general-payment breakdown at $2.6K, 100.0% of the reported total.
How Xiros Limited divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.6K | 1 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,625.00 (100.0%) of $2,625.00 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Xiros Limited
The five named recipients with the highest reported General Payments from this company
- 1
Kyle Borque
$2,625.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Xiros Limited's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Xiros Limited.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Xiros Limited.
Showing 6 of 1,924 companies with CMS-reported payment data.
Maquet Critical Care AB
Joline Medical Inc
McKesson Medical-Surgical, Inc.
Spectra Medical Devices, LLC
Kettenbach LP
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.